Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer (JCOG1113, FUGA-BT)

Trial Profile

Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer (JCOG1113, FUGA-BT)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2019

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Gemcitabine
  • Indications Adenocarcinoma; Biliary cancer; Carcinoma
  • Focus Therapeutic Use
  • Acronyms FUGA-BT
  • Most Recent Events

    • 19 Jan 2019 Results of a subgroup analysis presented at the 2019 Gastrointestinal Cancers Symposium
    • 05 Jun 2018 Results (n=354) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 20 Jan 2018 Primary endpoint (Overall survival) has been met, according to the results presented at the 2018 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top